Due to the complexity and heterogeneity of hepatocellular carcinoma, the existing clinical staging criterias are insufficient to accurately reflect the tumor microenvironment and predict the prognosis of HCC patients. Aggrephagy, as a type of selective autophagy, is associated with various phenotypes of malignant tumors.
OBJECTIVE:
This study aimed to identify and validate a prognostic model based on aggrephagy-related LncRNAs to assess the prognosis and immunotherapeutic response of HCC patients.
METHODS:
Based on the TCGA-LIHC cohort, aggrephagy-related LncRNAs were identified. Univariate Cox regression analysis and lasso and multivariate Cox regression were used to construct a risk-scoring system based on eight ARLs. CIBERSORT, ssGSEA, and other algorithms were used to evaluate and present the immune landscape of tumor microenvironment.
RESULTS:
The high-risk group had a worse overall survival (OS) than the low-risk group. Patients in the high-risk group are more likely to benefit from immunotherapy because of their high infiltration level and high immune checkpoint expression.
CONCLUSION:
The ARLs signature is a powerful predictor of prognosis for HCC patients, and the nomogram based on this model can help clinicians accurately determine the prognosis of HCC patients and screen for specific subgroups of patients who are more sensitive to immunotherapy and chemotherapy.
KimHLimHY. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. J Korean Med Sci.2011; 26(12): 1563-8.
2.
ZhouMWangHZengXYinPZhuJChenW, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet.2019; 394(10204): 1145-58.
3.
KoKPShinAChoSParkSKYooKY. Environmental contributions to gastrointestinal and liver cancer in the Asia-Pacific region. J Gastroenterol Hepatol.2018; 33(1): 111-20.
4.
YaoEChenJZhaoXZhengYWuXHanF, et al. Efficacy of stereotactic body radiotherapy for recurrent or residual hepatocellular carcinoma after transcatheter arterial chemoembolization. Biomed Res Int.2018; 2018: 5481909.
5.
IkaiIAriiSOkazakiMOkitaKOmataMKojiroM, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res.2007; 37(9): 676-91.
6.
ZhangZMLaiECZhangCYuHWLiuZWanBJ, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg.2015; 20: 8-16.
7.
XuDWangYZhouKWuJZhangZZhangJ, et al. Development and validation of a novel 8 immune gene prognostic signature based on the immune expression profile for hepatocellular carcinoma. Onco Targets Ther.2020; 13: 8125-40.
8.
YangLHuYZhouGChenQSongZ. Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways. Biosci Rep.2020; 40(7).
9.
LiuHTJiangMJDengZJLiLHuangJLLiuZX, et al. Immune checkpoint inhibitors in hepatocellular carcinoma: Current progresses and challenges. Front Oncol.2021; 11: 737497.
10.
WangHYuLCuiYHuangJ. G protein subunit gamma 5 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Dis Markers.2022; 2022: 1313359.
11.
ZhuJTangBLiJShiYChenMLvX, et al. Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Aging (Albany NY).2020; 12(9): 7848-73.
12.
BuXLiuSWenDKanAXuYLinX, et al. Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. Mol Ther Oncolytics.2022; 26: 226-44.
13.
LamarkTJohansenT. Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int J Cell Biol.2012; 2012: 736905.
14.
Garcia-MataRGaoYSSztulE. Hassles with taking out the garbage: aggravating aggresomes. Traffic.2002; 3(6): 388-96.
15.
KomatsuMKageyamaSIchimuraY. p62/SQSTM1/A170: Physiology and pathology. Pharmacol Res.2012; 66(6): 457-62.
16.
MoscatJDiaz-MecoMT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell.2009; 137(6): 1001-4.
17.
MathewRKarpCMBeaudoinBVuongNChenGChenHY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell.2009; 137(6): 1062-75.
18.
SunYQRichmondRCSudermanMMinJLBattramTFlatbergA, et al. Assessing the role of genome-wide DNA methylation between smoking and risk of lung cancer using repeated measurements: The HUNT study. Int J Epidemiol.2021; 50(5): 1482-97.
19.
LiuSJDangHXLimDAFengFYMaherCA. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer.2021; 21(7): 446-60.
20.
TabyRIssaJP. Cancer epigenetics. CA Cancer J Clin.2010; 60(6): 376-92.
21.
SahuASinghalUChinnaiyanAM. Long noncoding RNAs in cancer: From function to translation. Trends Cancer.2015; 1(2): 93-109.
22.
FriedmanJHastieTTibshiraniR. Regularization paths for generalized linear models via coordinate descent. J Stat Softw.2010; 33(1): 1-22.
23.
AranD. Cell-Type Enrichment Analysis of Bulk Transcriptomes Using xCell. Methods Mol Biol.2020; 2120: 263-76.
FinotelloFMayerCPlattnerCLaschoberGRiederDHacklH, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med.2019; 11(1): 34.
28.
PlattnerCFinotelloFRiederD. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Methods Enzymol.2020; 636: 261-85.
29.
DienstmannRVillacampaGSveenAMasonMJNiedzwieckiDNesbakkenA, et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann Oncol.2019; 30(10): 1622-9.
30.
ZhangHLiRCaoYGuYLinCLiuX, et al. Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients. Ann Surg.2022; 275(4): e626-e35.
31.
TammingaMHiltermannTJNSchuuringETimensWFehrmannRSGroenHJ. Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clin Transl Immunology.2020; 9(6): e1142.
32.
RacleJde JongeKBaumgaertnerPSpeiserDEGfellerD. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6.
33.
AuslanderNZhangGLeeJSFrederickDTMiaoBMollT, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med.2018; 24(10): 1545-9.
34.
XuLDengCPangBZhangXLiuWLiaoG, et al. TIP: A web server for resolving tumor immunophenotype profiling. Cancer Res.2018; 78(23): 6575-80.
35.
MariathasanSTurleySJNicklesDCastiglioniAYuenKWangY, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature.2018; 554(7693): 544-8.
36.
GeeleherPCoxNJHuangRS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol.2014; 15(3): R47.
37.
MayakondaALinDCAssenovYPlassCKoefflerHP. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res.2018; 28(11): 1747-56.
38.
RobinsonDRWuYMLonigroRJVatsPCobainEEverettJ, et al. Integrative clinical genomics of metastatic cancer. Nature.2017; 548(7667): 297-303.
39.
CuiGGengLZhuLLinZLiuXMiaoZ, et al. CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer. J Cancer.2021; 12(11): 3378-90.
40.
YanZGuoDTaoRYuXZhangJHeY, et al. Fluid shear stress induces cell migration via RhoA-YAP1-autophagy pathway in liver cancer stem cells. Cell Adh Migr.2022; 16(1): 94-106.
41.
SunJYYinTZhangXYLuXJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol.2019; 234(8): 12116-21.
42.
BruixJHessheimerAJFornerABoixLVilanaRLlovetJM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene.2006; 25(27): 3848-56.
43.
ZhangXGuanLTianHZengZChenJHuangD, et al. Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma. Front Oncol.2021; 11: 686962.
44.
HeimbachJKKulikLMFinnRSSirlinCBAbecassisMMRobertsLR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology.2018; 67(1): 358-80.
45.
MahmoodAAZhangJLiaoRPanXXuDXuH, et al. Evaluation of non-targeting, C- or N-pH (low) insertion peptide modified superparamagnetic iron oxide nanoclusters for selective MRI of liver tumors and their potential toxicity in cirrhosis. RSC Adv.2019; 9(25): 14051-9.
46.
YaoQZhangXChenD. Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases. Front Oncol.2022; 12: 848296.
47.
WangHLiaoPZengSXLuH. It takes a team: A gain-of-function story of p53-R249S. J Mol Cell Biol.2019; 11(4): 277-83.
48.
XuQHZhuPWLiBShiWQLinQMinYL, et al. Carbohydrate antigen-125, calcium, and hemoglobin as predictive clinical indicator for ocular metastasis in male liver cancer patients. Biosci Rep.2020; 40(2).
49.
CheYQZhangYLiHBShenDCuiW. Serum KLKB1 as a potential prognostic biomarker for hepatocellular carcinoma based on data-independent acquisition and parallel reaction monitoring. J Hepatocell Carcinoma.2021; 8: 1241-52.
50.
GaoYLiYSongZJinZLiXYuanC. Sortilin 1 promotes hepatocellular carcinoma cell proliferation and migration by regulating immune cell infiltration. J Oncol.2022; 2022: 6509028.
51.
KirkinVMcEwanDGNovakIDikicI. A role for ubiquitin in selective autophagy. Mol Cell.2009; 34(3): 259-69.
WangZZhangJLiuYZhaoRZhouXWangH. An Integrated Autophagy-Related Long Noncoding RNA Signature as a Prognostic Biomarker for Human Endometrial Cancer: A Bioinformatics-Based Approach. Biomed Res Int.2020; 2020: 5717498.
56.
TsaiTLWangHCHungCHLinPCLeeYSChenHHW, et al. Wheat germ agglutinin-induced paraptosis-like cell death and protective autophagy is mediated by autophagy-linked FYVE inhibition. Oncotarget.2017; 8(53): 91209-22.
57.
FanLLiHWangW. Long non-coding RNA PRRT3-AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy. Exp Physiol.2020; 105(5): 793-808.
58.
ChenDLiXLiHWangKTianX. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol.2022; 2022: 5313149.
59.
LuZTangFLiZLaiYLuZZhangJ, et al. Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer. Dis Markers.2022; 2022: 7931393.
60.
LiWCuiYMaWWangMCaiYJiangY. LncRNA RBPMS-AS1 promotes NRGN transcription to enhance the radiosensitivity of glioblastoma through the microRNA-301a-3p/CAMTA1 axis. Transl Oncol.2022; 15(1): 101282.
61.
SunYLiYShiSDongC. Exploiting a new approach to destroy the barrier of tumor microenvironment: Nano-architecture delivery systems. Molecules.2021; 26(9).
62.
TowerHRuppertMBrittK. The immune microenvironment of breast cancer progression. Cancers (Basel).2019; 11(9).
63.
WuXZShiXYZhaiKYiFSWangZWangW, et al. Activated naïve B cells promote development of malignant pleural effusion by differential regulation of T(H)1 and T(H)17 response. Am J Physiol Lung Cell Mol Physiol.2018; 315(3): L443-l55.
64.
BorstJAhrendsTBa̧bałaNMeliefCJMKastenmüllerW. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol.2018; 18(10): 635-47.
65.
ReiMPenningtonDJSilva-SantosB. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy. Cancer Res.2015; 75(5): 798-802.
66.
Silva-SantosBSerreKNorellH. γδ T cells in cancer. Nat Rev Immunol.2015; 15(11): 683-91.
67.
KalathilSGThanavalaY. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells.2021; 10(6).
68.
NinomiyaTAkbarSMMasumotoTHoriikeNOnjiM. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol.1999; 31(2): 323-31.
69.
ChenXDuYHuQHuangZ. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract.2017; 213(3): 245-9.
70.
MizukoshiENakamotoYAraiKYamashitaTSakaiASakaiY, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology.2011; 53(4): 1206-16.
71.
ZhouGSprengersDBoorPPCDoukasMSchutzHManchamS, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology.2017; 153(4): 1107-19.e10.
